Certara Inc. 2025年季度报告

(Exact name of registrant as specified in its charter) Table of Contents Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).YesxNoo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerginggrowth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of theExchange Act. Certara, Inc. Unless otherwise indicated, references to the “Company,” “Certara,” “we,” “us,” and “our” refer to Certara, Inc. and itsconsolidated subsidiaries. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains “forward-looking statements” within the meaningof Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the SecuritiesExchange Act of 1934, as amended (the “Exchange Act”), which are subject to the “safe harbor” created by those sections.All statements (other than statements of historical facts) in this Quarterly Report regarding the prospects of the industryand our prospects, plans, financial position and business strategy may constitute forward-looking statements. In addition,forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,”“should,” “expect,” “might,” “intend,” “will,” “estimate,” “anticipate,” “plan,” “seek,” “believe,” “predict,” “potential,” •anydeceleration in,or resistance to,the acceptance of model-informed biopharmaceutical discovery anddevelopment;•our ability to compete within our market;•changes or delays in government regulation relating to the biopharmaceutical industry;•trends in research and development (“R&D”) spending, the use of third parties by biopharmaceutical companiesand a shift toward more R&D occurring at smaller biotechnology companies;•consolidation within the biopharmaceutical industry;•our ability to successfully increase our customer base, expand our relationships and the products and services weprovide, and enter new markets;•our ability to retain key personnel or recruit additional qualified personnel;•risks related to the mischaracterization of our independent contractors; •our ability to successfully operate a global business;•adverse global economic conditions, including inflation, tariffs and/or trade disputes and fluctuating interest rates;•our ability to comply with applicable anti-corruption, trade compliance and economic sanctions laws andregulations; •risks related to litigation against us; •the loss of more than one of our major customers; •the ability or inability of our bookings to accurately predict our future revenue and our ability to realize the •our ability to reliably meet our data storage and management requirements, or the experience of any failures orinterruptions in the delivery of our services over the internet; •any unauthorized access to or use of customer or other proprietary or confidential data or other breach of ourcybersecurity measures; •the occurrence of natural disasters, pandemics, epidemic diseases, and public health crises, which may result indelays or cancellations of customer contracts or decreased utilization by our employees; •our ability to comply with the terms of any licenses governing our use of third-party open source software utilizedin our software solutions; •our ability to comply with applicable privacy and cybersecurity laws; •our ability to adequately enforce or defend our ownership and use of our intellectual property and other proprietary •any allegations that we are infringing, misappropriating or otherwise violating a third party’s intellectual propertyrights; •our ability to meet the obligations under our current or future indebtedness as they become due;•any limitations on our ability to pursue our business strategies due to restrictions under our current or futureindebtedness or inability to comply with any restrictions under such indebtedness; •any impairment of goodwill or other intangible assets; •the accuracy of our estimates and judgments relating to our critical accounting policies and any changes infinancial reporting standards or interpretations; •any inability to design, implement, and maintain effective internal controls when required by law, or inability totimely remediate internal controls that are deemed ineffective; and •the other factors described elsewhere in this Quarterly Report, in our Annual Report on Form 10-K for the fiscalyear ended December31, 2024 (“2024 Annual Report”), and in the other documents and reports we file with the Table of Contents You should not rely upon